LabCompass

Archana Shenoy

Medicine · The Ohio State University

Established · publishing since 1994

Publications

88

Citations

4,371

Est. group size

Recurring co-author estimate

Active years

33

Publishing since 1994

Research summary
AI-generated

Archana Shenoy's work focuses on the pathology and molecular characterization of pediatric and young adult soft tissue tumors, especially rhabdomyosarcoma and other sarcomas, using genetic and epigenetic markers to improve diagnosis and classification. This research also touches on related areas like cancer genomics, cell-free tumor DNA detection, and rare tumor case studies in children. The work is largely collaborative, often conducted through large pediatric cancer research consortia such as the Children's Oncology Group.

Pediatric sarcoma pathology and classificationMolecular and genetic characterization of tumorsRhabdomyosarcoma clinical outcomesCancer genomics and cell-free DNA diagnosticsRare pediatric tumor case studies

Publication output has been relatively steady over the past five years (averaging about 7 papers/year), following a peak period in 2019-2020, with continued consistent activity through 2024-2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 6.8/year recently
2017: 1 publication172018: 1 publication182019: 14 publications14192020: 12 publications202021: 5 publications212022: 7 publications222023: 5 publications232024: 9 publications242025: 7 publications252026: 6 publications26
Recent publications
Publishes in
  • Pediatric and Developmental Pathology×5
  • Journal of Clinical Oncology×5
  • Pediatric Blood & Cancer×4
  • Fetal and Pediatric Pathology×3
  • Archives of Pathology & Laboratory Medicine×3
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile